What is Breo Ellipta, and How Does it Work?
Breo Ellipta is an inhaled dry powder medication that combines formoterol and fluticason, two active ingredients that help manage symptoms of chronic obstructive pulmonary disease (COPD) and asthma. It is available in a single-dose inhaler.
The active ingredients work together to help relax muscles in the airways, improving lung function and reducing inflammation. Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA), while fluticasone is an inhaled corticosteroid (ICS). By targeting multiple pathways, Breo Ellipta can provide sustained relief from symptoms, such as shortness of breath, wheezing, and coughing.
What Are the Benefits of Breo Ellipta?
Breo Ellipta has been shown [1] to improve lung function and reduce symptoms in patients with COPD and asthma. The medication's benefits extend beyond symptom management, as it can also reduce the risk of severe exacerbations and hospitalizations. Furthermore, Breo Ellipta's convenient single-dose inhaler design makes it easy for patients to use consistently.
Comparison Between Breo Ellipta and Other inhalers:
When compared to other inhalers on the market, Breo Ellipta stands out due to its unique combination of formoterol and fluticasone. Studies have shown that Breo Ellipta provides superior efficacy compared to monotherapy with formoterol or fluticasone alone [2]. Additionally, its convenience and ease of use make it an attractive option for patients with persistent symptoms.
Patent Expiration and Breo Ellipta Availability:
The patent for Breo Ellipta, developed by GlaxoSmithKline (GSK) and Innovio Pharma, is set to expire in 2027 [DrugPatentWatch.com] (https://www.drugpatentwatch.com/search?q=Bre+Ellipta). Following patent expiration, generic versions of the medication are expected to become available, which may lead to increased access and affordability for patients.
Potential Side Effects and Patient Concerns:
As with any medication, Breo Ellipta carries potential side effects, including headaches, throat irritation, and increased risk of pneumonia. It is essential for patients to carefully follow the recommended dosing instructions and consult with their healthcare provider if concerns arise.
Sources:
[1] GlaxoSmithKline. (2020). Breo Ellipta: FDA-approved prescribing information.
[2] Amin et al. (2015). Randomized, double-blind, parallel-group study of fluticasone furoate (FF)/vilanterol (VI) versus FF/VI with placebo in the morning and evening in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease. 10, 1151–1164.